Abstract
Bladder urothelial cell carcinoma (UCC) incidence is about three times higher in men compared with women. There are several indications for the involvement of hormonal factors in the aetiology of UCC. Here, we provide evidence of androgen signalling in UCC progression. Microarray and qPCR analysis revealed that the androgen receptor (AR) mRNA level is upregulated in a subset of UCC cases. In an AR‐positive UCC‐derived cell line model, UM‐UC‐3‐AR, androgen treatment increased clonogenic capacity inducing the formation of big stem cell‐like holoclones, while AR knockdown or treatment with the AR antagonist enzalutamide abrogated this clonogenic advantage. Additionally, blockage of AR signalling reduced the cell migration potential of androgen‐stimulated UM‐UC‐3‐AR cells. These phenotypic changes were accompanied by a rewiring of the transcriptome with almost 300 genes being differentially regulated by androgens, some of which correlated with AR expression in UCC patients in two independent data sets. Our results demonstrate that AR signals in UCC favouring the development of an aggressive phenotype and highlights its potential as a therapeutic target for bladder cancer.
Highlights
Bladder urothelial cell carcinoma (UCC) is the 12th most commonly diagnosed malignancy worldwide and the 14th leading cause of cancer death among men and women [1]
Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies
androgen receptor (AR) mRNA expression was significantly higher in nonmuscle invasive bladder cancer (NMIBC) compared with muscle-invasive bladder cancer (MIBC) tissues (Fig. 1B), and a trend towards lower AR expression and tumour stage was observed
Summary
Bladder urothelial cell carcinoma (UCC) is the 12th most commonly diagnosed malignancy worldwide and the 14th leading cause of cancer death among men and women [1]. Abbreviations ADT, androgen deprivation therapy; AR, androgen receptor; CIS, in situ carcinoma; Cp, crossing point; CSS, charcoal-stripped serum; CYP, cytochrome P450; FDR, false discovery rate; GSEA, gene set enrichment analysis; ICC, immunocytochemistry; IHC, immunohistochemistry; MIBC, muscle-invasive bladder cancer; NES, normalized enrichment scores; NMIBC, nonmuscle invasive bladder cancer; PC, principal component; PCA, principal component analysis; PCa, prostate cancer; PSA, prostate-specific antigen; siRNAs, small interfering RNAs; TCGA, The Cancer Genome Atlas; UCC, bladder urothelial cell carcinoma. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
